Literature DB >> 18310303

Novel CYP2C9 promoter variants and assessment of their impact on gene expression.

Melissa A Kramer1, Allan E Rettie, Mark J Rieder, Erwin T Cabacungan, Ronald N Hines.   

Abstract

There are a considerable number of reports identifying and characterizing genetic variants within the CYP2C9 coding region. Much less is known about polymorphic promoter sequences that also might contribute to interindividual differences in CYP2C9 expression. To address this problem, approximately 10,000 base pairs of CYP2C9 upstream information were resequenced using 24 DNA samples from the Coriell Polymorphism Discovery Resource. Thirty-one single-nucleotide polymorphisms (SNPs) were identified; nine SNPs were novel, whereas 22 were reported previously. Using both sequencing and multiplex single-base extension, individual SNP frequencies were determined in 193 DNA samples obtained from unrelated, self-reported Hispanic Americans of Mexican descent, and they were compared with similar data obtained from a non-Latino white cohort. Significant interethnic differences were observed in several SNP frequencies, some of which seemed unique to the Hispanic population. Analysis using PHASE 2.1 inferred nine common (>1%) variant haplotypes, two of which included the g.3608C>T (R144C) CYP2C9(*)2 and two the g.42614A>C (I359L) CYP2C9(*)3 SNPs. Haplotype variants were introduced into a CYP2C9/luciferase reporter plasmid using site-directed mutagenesis, and the impact of the variants on promoter activity assessed by transient expression in HepG2 cells. Both constitutive and pregnane X receptor-mediated inducible activities were measured. Haplotypes 1B, 3A, and 3B each exhibited a 65% decrease in constitutive promoter activity relative to the reference haplotype. Haplotypes 1D and 3B exhibited a 50% decrease and a 40% increase in induced promoter activity, respectively. These data suggest that genetic variation within CYP2C9 regulatory sequences is likely to contribute to differences in CYP2C9 phenotype both within and among different populations.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310303      PMCID: PMC2413059          DOI: 10.1124/mol.107.044149

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  40 in total

1.  Strong bias in the location of functional promoter polymorphisms.

Authors:  Paul R Buckland; Bastiaan Hoogendoorn; Sharon L Coleman; Carol A Guy; S Kaye Smith; Michael C O'Donovan
Journal:  Hum Mutat       Date:  2005-09       Impact factor: 4.878

2.  Transcriptional regulation of the human hepatic CYP3A4: identification of a new distal enhancer region responsive to CCAAT/enhancer-binding protein beta isoforms (liver activating protein and liver inhibitory protein).

Authors:  Celia P Martínez-Jiménez; M José Gómez-Lechón; José V Castell; Ramiro Jover
Journal:  Mol Pharmacol       Date:  2005-03-18       Impact factor: 4.436

3.  CYP2C9 haplotype structure in European American warfarin patients and association with clinical outcomes.

Authors:  David L Veenstra; David K Blough; Mitchell K Higashi; Frederico M Farin; Sengkeo Srinouanprachan; Mark J Rieder; Allan E Rettie
Journal:  Clin Pharmacol Ther       Date:  2005-05       Impact factor: 6.875

4.  5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.

Authors:  Harumi Takahashi; Ichiro Ieiri; Grant R Wilkinson; Gail Mayo; Toshitaka Kashima; Sosuke Kimura; Kenji Otsubo; Hirotoshi Echizen
Journal:  Blood       Date:  2003-12-30       Impact factor: 22.113

5.  The impact of CYP2C9 genetics and oral contraceptives on cytochrome P450 2C9 phenotype.

Authors:  Mia Sandberg; Inger Johansson; Magnus Christensen; Anders Rane; Erik Eliasson
Journal:  Drug Metab Dispos       Date:  2004-05       Impact factor: 3.922

6.  Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.

Authors:  Farhad Kamali; Tayyaba Irfan Khan; Barry P King; Richard Frearson; Patrick Kesteven; Peter Wood; Ann K Daly; Hilary Wynne
Journal:  Clin Pharmacol Ther       Date:  2004-03       Impact factor: 6.875

7.  Involvement of hepatocyte nuclear factor 4alpha in the different expression level between CYP2C9 and CYP2C19 in the human liver.

Authors:  Sachiyo Kawashima; Kaoru Kobayashi; Kaori Takama; Tomoaki Higuchi; Tomomi Furihata; Masakiyo Hosokawa; Kan Chiba
Journal:  Drug Metab Dispos       Date:  2006-03-15       Impact factor: 3.922

8.  Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.

Authors:  Brian F Gage; Charles Eby; Paul E Milligan; Gerald A Banet; Jill R Duncan; Howard L McLeod
Journal:  Thromb Haemost       Date:  2004-01       Impact factor: 5.249

Review 9.  Clinical relevance of genetic polymorphisms in the human CYP2C9 gene.

Authors:  U I Schwarz
Journal:  Eur J Clin Invest       Date:  2003-11       Impact factor: 4.686

10.  The nuclear receptors constitutive androstane receptor and pregnane X receptor cross-talk with hepatic nuclear factor 4alpha to synergistically activate the human CYP2C9 promoter.

Authors:  Yuping Chen; Grace Kissling; Masahiko Negishi; Joyce A Goldstein
Journal:  J Pharmacol Exp Ther       Date:  2005-05-26       Impact factor: 4.030

View more
  8 in total

1.  CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.

Authors:  Danxin Wang; Xiaochun Sun; Yan Gong; Brian E Gawronski; Taimour Y Langaee; Mohamed Hossam A Shahin; Sherief I Khalifa; Julie A Johnson
Journal:  Drug Metab Dispos       Date:  2012-01-30       Impact factor: 3.922

Review 2.  Pharmacogenetics of drug-metabolizing enzymes in US Hispanics.

Authors:  Karla Claudio-Campos; Jorge Duconge; Carmen L Cadilla; Gualberto Ruaño
Journal:  Drug Metab Pers Ther       Date:  2015-06

Review 3.  Cytochrome P450 2C9-CYP2C9.

Authors:  Derek Van Booven; Sharon Marsh; Howard McLeod; Michelle Whirl Carrillo; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

4.  Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma.

Authors:  Andrew T Chan; Ann G Zauber; Meier Hsu; Aurora Breazna; David J Hunter; Rebecca B Rosenstein; Craig J Eagle; Ernest T Hawk; Monica M Bertagnolli
Journal:  Gastroenterology       Date:  2009-02-21       Impact factor: 22.682

5.  CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.

Authors:  Amarjit S Chaudhry; Thomas J Urban; Jatinder K Lamba; Angela K Birnbaum; Rory P Remmel; Murali Subramanian; Stephen Strom; Joyce H You; Dalia Kasperaviciute; Claudia B Catarino; Rodney A Radtke; Sanjay M Sisodiya; David B Goldstein; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-10-23       Impact factor: 4.030

6.  Association of polymorphism in cytochrome P450 2C9 with susceptibility to head and neck cancer and treatment outcome.

Authors:  Sunishtha S Yadav; Shilpi Seth; Anwar J Khan; Shailendra S Maurya; Ankur Dhawan; Sidharth Pant; Mohan C Pant; Devendra Parmar
Journal:  Appl Transl Genom       Date:  2013-08-27

Review 7.  Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.

Authors:  Ann K Daly; Allan E Rettie; Douglas M Fowler; John O Miners
Journal:  J Pers Med       Date:  2017-12-28

8.  Impact of a variable number tandem repeat in the CYP2C9 promoter on warfarin sensitivity and responsiveness in Jordanians with cardiovascular disease.

Authors:  Laith N Al-Eitan; Ayah Y Almasri; Sahar O Al-Habahbeh
Journal:  Pharmgenomics Pers Med       Date:  2019-03-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.